Compare BTU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | IDYA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | BTU | IDYA |
|---|---|---|
| Price | $28.35 | $33.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $26.71 | ★ $49.42 |
| AVG Volume (30 Days) | ★ 2.6M | 926.1K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,962,300,000.00 | $214,834,000.00 |
| Revenue This Year | N/A | $2,434.86 |
| Revenue Next Year | $19.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $9.61 | $13.45 |
| 52 Week High | $35.99 | $37.08 |
| Indicator | BTU | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 49.04 |
| Support Level | $27.51 | $33.12 |
| Resistance Level | $30.29 | $37.08 |
| Average True Range (ATR) | 1.40 | 1.49 |
| MACD | 0.15 | -0.37 |
| Stochastic Oscillator | 58.33 | 3.02 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.